Teva Pharmaceutical Industries (TEVA) Inventory (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Inventory across 18 years of filings, most recently posting $3.2 billion for Q1 2026.

• Quarterly Inventory fell 2.19% year-over-year to $3.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 billion (down 2.19% YoY) and the FY2025 annual result came in at $3.2 billion, up 5.72% from the prior year.
• Inventory was little changed at $3.2 billion in Q1 2026, from $3.2 billion in the prior quarter.
• Over five years, Inventory peaked at $4.1 billion in Q1 2023 and troughed at $3.0 billion in Q4 2024.
• A 5-year average of $3.7 billion and a median of $3.9 billion in 2024 frame the typical range for Inventory.
• Annual changes were most pronounced in 2024 — Inventory dropped 25.22% — and 2025, when it rose 5.72%.
• Tracing TEVA's Inventory over 5 years: stood at $3.8 billion in 2022, then rose by 4.9% to $4.0 billion in 2023, then fell by 25.22% to $3.0 billion in 2024, then advanced by 5.72% to $3.2 billion in 2025, then slipped by 0.09% to $3.2 billion in 2026.
• Business Quant data shows TEVA's Inventory at $3.2 billion in Q1 2026, $3.2 billion in Q4 2025, and $3.3 billion in Q3 2025.